Stoke Therapeutics, Inc.
STOKDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
4wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How STOK's past catalysts played out
zorevunersen
Dravet Syndrome
STK-001 - Single Ascending Doses
Dravet Syndrome
STK-001
Dravet Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
zorevunersen | Phase 3 | Dravet Syndrome | - | - |
STK-001 - Single Ascending Doses | Phase 2 | Dravet Syndrome | - | - |
STK-001 | Phase 2 | Dravet Syndrome | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Stoke Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Stoke Therapeutics, Inc.'s (STOK) pipeline across Phase 3, Phase 2. Its lead program is zorevunersen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Stoke Therapeutics, Inc.'s next FDA catalyst?→
Stoke Therapeutics, Inc.'s (STOK) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track STOK biotech catalysts?→
Add STOK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Stoke Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.